Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 115.01 USD 2.23%
Market Cap: 2.2B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LGND Price Targets Summary
Ligand Pharmaceuticals Inc

Wall Street analysts forecast LGND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LGND is 146.75 USD with a low forecast of 136.35 USD and a high forecast of 164.85 USD.

LGND Lowest Forecast
Wall Street Target
136.35 USD
19% Upside
LGND Average Forecast
Wall Street Target
146.75 USD
28% Upside
LGND Highest Forecast
Wall Street Target
164.85 USD
43% Upside
Lowest
Price Target
136.35 USD
19% Upside
Average
Price Target
146.75 USD
28% Upside
Highest
Price Target
164.85 USD
43% Upside
Ligand Pharmaceuticals Inc Competitors:
Price Targets
IVA
Inventiva SA
216% Upside
SWTX
SpringWorks Therapeutics Inc
14% Upside
SPRY
ARS Pharmaceuticals Inc
117% Upside
1530
3SBio Inc
1% Downside
IVA
Inventiva SA
216% Upside
SWTX
SpringWorks Therapeutics Inc
14% Upside
SPRY
ARS Pharmaceuticals Inc
117% Upside
1530
3SBio Inc
1% Downside
PHM
Pharma Mar SA
13% Upside
S
SVE
Synthaverse SA
32% Upside
E
1952
Everest Medicines Ltd
8% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
10% Downside

Revenue
Forecast

Revenue Estimate
Ligand Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Ligand Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 18%.

14%
Past Growth
18%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ligand Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Ligand Pharmaceuticals Inc's operating income is 21%. The projected CAGR for the next 3 years is 82%.

21%
Past Growth
82%
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ligand Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
LGND intrinsic value, competitors valuation, and company profile.
DCF Valuation
LGND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LGND stock valuation using valuation multiples.
Wall Street Estimates
LGND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LGND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LGND's stock price target?
Price Target
146.75 USD

According to Wall Street analysts, the average 1-year price target for LGND is 146.75 USD with a low forecast of 136.35 USD and a high forecast of 164.85 USD.

What is Ligand Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%

For the last 13 years the compound annual growth rate for Ligand Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 18%.

What is Ligand Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
82%

For the last 13 years the compound annual growth rate for Ligand Pharmaceuticals Inc's operating income is 21%. The projected CAGR for the next 3 years is 82%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.